Table 1.
Amount of patient motion per subject (in mm)
| Tracer | Subject | Mean over all subjects | |||||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | |||
| Average motion during emission scan over all time frames | (R)-[11C]verapamil | 1.8 | 2.1 | 3.4 | 2.2 | 5.2 | 3.0 |
| [11C]raclopride | 3.1 | 2.6 | 1.6 | 4.5 | 1.7 | 2.7 | |
| [11C]flumazenil | 2.9 | 2.3 | 0.9 | 1.5 | 2.4 | 2.0 | |
| Maximum motion during emission scan over all time frames | (R)-[11C]verapamil | 4.2 | 5.9 | 5.2 | 4.5 | 7.7 | 5.5 |
| [11C]raclopride | 10.0 | 5.2 | 3.7 | 7.7 | 2.7 | 5.9 | |
| [11C]flumazenil | 4.2 | 2.7 | 2.2 | 2.9 | 4.6 | 3.3 | |
| Motion between transmission and emission data | (R)-[11C]verapamil | 4.2 | 5.9 | 3.8 | 4.5 | 5.5 | 4.8 |
| [11C]raclopride | 2.0 | 4.5 | 3.3 | 2.1 | 2.7 | 2.9 | |
| [11C]flumazenil | 3.2 | 2.2 | 1.7 | 2.9 | 4.6 | 2.9 | |